Clinical Trial Update: Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating safety, tolerability, and efficacy of UCB7665 in subjects with primary immune thrombocytopenia has been completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• UCB7665

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Thrombocytopenia | Phase 2 | Status: COMPLETED | Results posted: 2024-01-29